AZ-11713908

AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB₁ receptor and a partial agonist at CB₂. It has poor blood–brain barrier penetration, and so while it is an effective analgesic in animal tests, it produces only peripheral effects at low doses, with much weaker symptoms of central effects compared to other cannabinoid drugs such as WIN 55,212-2.^[1] Many related benzimidazole-derived cannabinoid ligands are known.^[2][3][4][5]

AZ-11713908

Identifiers
IUPAC name N-(1-(cyclohexylmethyl)-2-((5-ethoxypyridin-2-yl)methyl)-1H-benzo[d]imidazol-5-yl)-N-methylthiophene-2-sulfonamide
CAS Number	1309682-69-6 N
ChemSpider	26286889 Y
UNII	MN7RR3VQL7
Chemical and physical data
Formula	C27H32N4O3S2
Molar mass	524.70 g·mol−1
3D model (JSmol)	Interactive image
SMILES c5ccsc5S(=O)(=O)N(C)c3ccc1c(c3)nc(Cc(cc2)ncc2OCC)n1CC4CCCCC4
InChI InChI=1S/C27H32N4O3S2/c1-3-34-23-13-11-21(28-18-23)16-26-29-24-17-22(30(2)36(32,33)27-10-7-15-35-27)12-14-25(24)31(26)19-20-8-5-4-6-9-20/h7,10-15,17-18,20H,3-6,8-9,16,19H2,1-2H3 Y Key:YIEVWZCZMDYKQH-UHFFFAOYSA-N Y
NY (what is this?)

See also

• AM-6545
• AZD-1940
• CB-13
• RQ-00202730